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Systems Toxicology Approach to Identifying Paracetamol
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Paracetamol (acetaminophen (APAP)) is one of the most commonly used analgesics in the United Kingdom and the United
States. However, exceeding the maximum recommended dose can cause serious liver injury and even death. Promising APAP
toxicity biomarkers are thought to add value to those used currently and clarification of the functional relationships between
these biomarkers and liver injury would aid clinical implementation of an improved APAP toxicity identification framework.
The framework currently used to define an APAP overdose is highly dependent upon time since ingestion and initial dose;
information that is often highly unpredictable. A pharmacokinetic/pharmacodynamic (PK/PD) APAP model has been built in
order to understand the relationships between a panel of biomarkers and APAP dose. Visualization and statistical tools have
been used to predict initial APAP dose and time since administration. Additionally, logistic regression analysis has been
applied to histology data to provide a prediction of the probability of liver injury.
CPT Pharmacometrics Syst. Pharmacol. (2018) 00, 00; doi:10.1002/psp4.12298; published online on 0 Month 2017.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 The current clinical framework for predicting para-
cetamol overdose is imprecise, predominantly due to
a dependency on uncertain information from patients,
such as dose amount and time since administration.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Mathematical modeling and statistical methods are
applied to predict dose, time-since-administration, and
the probability of paracetamol-induced liver injury based
on biomarker information by exploiting the relative
abundance and quality of mouse data.
WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
 A new in silico paracetamol toxicity identification
framework is described to simulate the PK/PD
behavior of paracetamol and a panel of correspond-
ing toxicity biomarkers with considerable translational
potential.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 Systems toxicology approaches to direct biomarker
identification and optimization can also be used to
develop predictive modeling frameworks for other
hepatotoxic drugs. An understanding of complex bio-
logical system interactions is required to refine
potential treatment strategies and improve safety,
ethics, and cost-efficiency. Mathematical modeling
provides an enhanced mechanistic understanding,
whereas statistical modeling can provide robust,
physiologically relevant predictions to underpin future
investigations.
Paracetamol (acetaminophen (APAP)) is the most com-
monly used painkiller in the world1 and the leading cause
for acute liver failure in the Western world.2 The current
antidote used to treat cases of APAP overdose, N-
acetylcysteine (NAC), reduces the likelihood of progression
into drug-induced liver injury (DILI).3 NAC is highly effective
when administered within 8–10 hours of initial APAP dose.4
Although NAC is currently the most effective APAP over-
dose treatment, there are many adverse side effects, such
as rash, vomiting, and anaphylactoid reaction.3 The decision
to administer NAC is currently based upon the nomogram
treatment line,5 which is influenced by a measurement of ala-
nine aminotransferase (ALT), but is also heavily dependent
on the initial dose amount and time elapsed since ingestion,6
information that is often highly unpredictable within the clinical
setting.
ALT elevation represents probable liver injury postoccur-
rence7 and is the most widely used blood-based biomarker
for measuring DILI.8 Aspartate aminotransferase (AST) is
another DILI biomarker8 that accumulates in the blood due
to liver damage, but it is also linked to other pathologies
(e.g., heart injury).9 Increased serum total bilirubin is indica-
tive of the substantial loss of functional hepatocytes; there-
fore, similar to ALT, this biomarker does not predict
hepatotoxicity potential but instead is a postoccurrence indi-
cator.7 In order to improve the treatment of APAP-induced
DILI via NAC therapy, biomarkers are required that can predict
liver damage a priori. Although there are clear limitations,
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clinics currently analyze changes in ALT, AST, and total biliru-
bin in combination to predict DILI.10 Recently, biomarkers
K18 and HMGB1 have been shown to add value to the mea-
surement of ALT11 and have the potential to predict DILI pre-
occurrence. However, such new biomarkers are often exam-
ined singly and clarification of their functional relationships is
required to aid clinical implementation.12 For a thorough
review of the mechanisms of DILI see, for example, ref. 13.
In silico modeling allows for the development of mecha-
nistic understanding of biological systems, which may not
always be possible from in vitro/in vivo experiments alone.
An interdisciplinary, systems toxicology approach is a cost-
effective way of understanding and predicting drug efficacy
and toxicology while complying with the 3R’s (scientific
framework for use of animals in research).14 There have
been multiple in silico models that have been previously
developed to study APAP metabolism and associated toxic
potential. Reith et al.15 produced a system of equations
with parameters fitted to human data consisting of patients
dosed with pain relievers to provide clarification of the role
of the glucuronidation and sulfation pathways, providing a
basis for examining APAP metabolism in various disease
states. Diaz Ochoa et al.16 took a multiscale approach by
first creating a spatiotemporal prediction of drug and
metabolite concentrations within the liver, and then at the
whole-body level, including blood-flow between organs.
Remien et al.17 created a model for acetaminophen-
induced liver damage and derived ordinary differential
equations (ODEs) describing changes in AST, ALT, and
INR. The authors optimized initial APAP dose amount and
time since overdose by fitting the resulting ODEs to clinical
data (from 53 patients who overdosed). Remien et al.18
then extended this framework to a cell-based model. Our
study extends Remien’s approach by combining ALT with
additional biomarkers that have the potential to predict
APAP-induced liver injury pre-occurrence. Additionally, the
study is extended to nonoverdose and overdose cases in
an attempt to identify the key biomarkers that discriminate
between the two situations. Ben-Shachar et al.19 created a
retrospective study complementary to Remien’s model.
Although Remien’s model aimed to predict overdose occur-
rence, Ben-Shachar’s model was used to determine whether
an overdose would lead to fatal liver damage. Reddyhoff
et al.20 constructed a cell-based model that described major
pathways impacting on APAP clearance. Sensitivity analysis
determined which parameters had the largest effect on the
progression to toxicity. Shoda et al.21 mechanistically mod-
eled the biomarker HMGB1. Their focus was the role of
HMGB1 with regard to the innate immune response and con-
cluded that HMGB1 was a key input for immune cell
activation.
In this report, our focus is to investigate HMBG1 within a
panel of DILI biomarkers, attempting to predict APAP toxic-
ity in mice. We propose a novel framework to predict initial
APAP dose, time-since-administration, and the probability
of APAP-induced liver injury. The platform is distinctive pri-
marily due to the use of promising biomarkers, optimized
within the pharmacokinetic/pharmacodynamic (PK/PD)
framework by combining the use of deterministic modeling
with statistical analysis. The mouse is widely considered to
be a good model for APAP toxicity prediction in humans22
and we have utilized mouse-derived data in this study to
develop our new in silico framework by exploiting the rich
datasets available and also to avoid, at this early stage of
model development, the uncertainties associated with
APAP human overdose data. Translation to the human clini-
cal case would be, in theory, a relatively simple adjustment
of the PK/PD model parameters, which could be estimated
from a population-pharmacokinetic (Pop-PK) analysis of
clinical overdose data.23 However, the key feature of this
current work is to demonstrate the development and valida-
tion of our new predictive framework using the more ame-
nable mice data. The results from our investigation define
currently undocumented pharmacokinetic (PK) parameters
for APAP in mice, and the biomarkers are examined as a
panel, rather than individually. Additionally, the focus of this
work is the biomarkers that work well for DILI prediction
due to APAP, which may only represent certain pathways or
mechanisms that are not applicable with other drugs but
we anticipate that this in silico approach can be translated
across drug space with the necessary biomarker data.
METHODS
Model development (i) – APAP pharmacokinetics
Four datasets from two separate published studies24,25
recording APAP concentration over time in mice following
intraperitoneal administration of 50, 150, 500, and 530 mg/
kg doses were used to parameterize a two-compartment
PK model describing APAP metabolism in mice. Note that
for applications to oral administration, the absorption rate
parameter, ka, would be multiplied by a bioavailability frac-
tion to implicitly take into account effects of gastric empty-
ing and absorbed fraction (details of the model selection
can be found in the Supplementary Material).
Two ODEs were used to represent changes in APAP con-
centration within two PK compartments (central and periph-
eral) of the mice in the following system:
dCc
dt
5
kaD0e2ka t
Vc
1k21Cp
Vp
Vc
2k12Cc2kelCc ; (1)
dCp
dt
5 k12Cc
Vc
Vp
2k21Cp ; (2)
where Cc represents the central compartment concentration
of APAP (lmol/l), Cp represents the peripheral compartment
concentration of APAP (lmol/l), ka represents the absorption
rate from the peritoneal cavity (h21), D0 represents initial
dose (mg), k21 represents the transfer rate from the periph-
eral to the central compartment (h21), k12 represents the
transfer rate from the central to the peripheral compartment
(h21), Vp represents the theoretical volume of the peripheral
compartment (l/kg), Vc represents the theoretical volume of
the central compartment (l/kg), kel represents the overall
elimination rate (summation of both excretion and metabo-
lism processes) (h21), and t represents the time variable (h).
Solving both equations analytically through Laplace trans-
forms26 gives the following equation for paracetamol concen-
tration in the central compartment as a function of time:
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where a and b are related to the model parameters as
follows:
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;
and
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2
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:
Eq. 3 was fitted to the four aforementioned datasets simul-
taneously using a Nelder-Mead search algorithm,27 with
parameters ka; k21; Vc ; a, and b being optimized in order to
minimize the difference between the model output and the
observed APAP dynamics. Note that all subsequent data fit-
ting also uses this algorithm. Data fitting was performed
using the fminsearch tool in Matlab.28 Optimized parameter
values and model simulation codes are provided in the
Supplementary Material.
Model development (ii) – glutathione depletion
The role of glutathione (GSH) in APAP metabolism is to detox-
ify N-acetyl-p-benzoquinoeimine (NAPQI), a highly reactive
metabolite13 formed following the bioactivation of APAP. There-
fore, GSH stores are depleted in the case of an overdose and
NAPQI accumulates, eventually causing liver damage. In our
model, paracetamol biomarker response dynamics were
assumed to be directly dependent on GSH depletion. The
GSH parameter values were optimized such that the solution
was fitted to GSH time-course data from a literature study.25
GSH dynamics are described in the Eq. 4 below:
d gsh½ 
dt
5ko  gsh02ko  gsh2 n  kel  Cc  gshgsh1kpr ; (4)
where ko is the basal removal rate (including background
usage) of GSH (h21), gsh0 is the baseline value of GSH
(lmol/l) in the APAP-free steady state, n is the proportion
of eliminated APAP that is transformed into NAPQI, and kpr
is the ratio of NAPQI forming other protein adducts relative
to NAPQI detoxified by GSH. The APAP elimination rate,
kel , was identified during PK model development (above),
whereas all other parameters were optimized by fitting
Eq. 4 to the data in Antoine et al.25 Further information,
and full derivation of the GSH ODE in Eq. 4 is described in
the Supplementary Material.
Model development (iii) – pharmacodynamics
The toxic response to APAP overdose was mathematically
described with individual pharmacodynamic (PD) models
representing biomarker concentrations (r 5ALT, HMGB1,
K18, and fragmented K18) over time, as described in Eq. 5:
dr
dt
5r0kout
Rn501gsh
n
0
Rn50
 
12
gshn
Rn501gsh
n
 
2kout r ; (5)
where r0 is the biomarker baseline concentration, kout is
the natural decay rate of the biomarker (h21), R50 repre-
sents the concentration of GSH, which causes the bio-
marker production (response) to be half its maximal value
(lmol/l), and n is a parameter that reflects the steepness of
the biomarker production term.29 Further model details can
be found in the Supplementary Material. Although param-
eter values r0 and gsh0 can be identified directly from the
data, kout ; R50; and n were optimized by individually fitting
the model output to data measuring biomarker concentra-
tion over time following a 530 mg/kg dose of APAP.25
Model validation
The parameterized PK/PD model was validated against
data from a separate experiment (detailed below). The PK/
PD model simulated several dosing scenarios 0, 150, 300,
and 530 mg/kg and biomarker concentration outputs were
extracted at 5 hours and compared with the experimental
data. Further details and results can be found in the Sup-
plementary Figure S1.
Experimental animal treatment
The protocols described were undertaken in accordance
with criteria outlined in a license granted under the Animals
(Scientific Procedures) Act 1986 and approved by the Uni-
versity of Liverpool Animal Ethics Committee. Groups of six
individual CD-1 male mice (25–35 g) with free access to
food and water were included in the study. For the biomarker
time-course, treatment was as previously described.25 For the
dose/response data used for validation, study animals were
administered a 150, 300, or 530 mg/kg i.p. APAP injection
and were euthanized 5 hours post-treatment. The 5-hour time
point has been used in previous studies,25 and was chosen
here not only because the pathological and biomarker
response has been extensively categorized at this point, but
the majority of key mechanisms (apoptosis, necrosis, and
inflammation) are also identifiable at this time point. Control
animals received either 0.9% saline or solvent control in 0.9%
saline as appropriate. Serum ALT activity, HMGB1, and frag-
mented K18 levels were determined, and GSH content
assessment was carried out on the livers of all animals. Total
hepatic glutathione (GSH and oxidized glutathione) levels and
biomarker quantification/characterization were determined as
described previously.25,30
PREDICTING TIME SINCE ADMINISTRATION AND
INITIAL DOSE
Multiple linear regression
The in silico model was used to create virtual datasets for
testing and validation (Methodology in Supplementary
Material). A robust multiple linear regression model31 was
fitted to the in silico derived data to predict time-since-
administration and initial dose.
Visualization
Principal component analysis (PCA),32 and the T-SNE
method33 were applied to visualize the simulated in silico
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datasets with regard to linear combinations of all variables
(APAP and toxicity biomarkers combined) for each in silico
individual.
Classification
Appropriate classes for each dose and time range were
identified to see if the time-since-administration and dose
amount could be predicted for a new individual within the
population. Various classification techniques (detailed in
Supplementary Material) appropriate for such a task were
used and compared.
Predicting probability of liver injury
The biomarker time-course experimental data used to create
the PD model25 also provided a corresponding histology score
for each mouse from the range 0, 1, 2, and 3. These histology
scores were binarized based upon previously published
criteria.25 Forward-stepwise binary logistic regression34 was
applied in order to understand the most significant biomarker
or panel of biomarkers for DILI. The most significant bio-
markers were then used in combination with PK/PD model
simulations to predict the DILI probability.35
Further details of all aforementioned statistical techniques
can be found in the Supplementary Material.
RESULTS
Results from the parameter optimization of the PK/PD mod-
els can be seen in Figure 1. Note that sufficient early time
experimental APAP plasma concentrations are currently
unavailable, which would verify the accuracy of time of
maximum plasma concentration (Tmax) and peak plasma
concentration (Cmax) of the 530-mg dose. Nevertheless,
(a) (b)
(c) (d)
(e) (f)
Figure 1 In silico simulation outputs from the optimized model compared with the experimental data. (a) Acetaminophen (APAP) phar-
macokinetic simulations (solid lines) comparable to original data values with green, black, magenta, and red representing APAP time-
course following a 50, 150, 500, and 530 mg/kg dose, respectively. (b) Glutathione (GSH) simulations (black dashed lines) comparable
to original data (blue). Individual pharmacodynamic simulation (black dashed lines) comparable to data (blue) for biomarkers alanine
aminotransferase (ALT) (c), HMGB1 (d), full K18 (e), and fragmented K18 (f).
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with an R2 value of 0.8304 for the PK model, and values of
0.7513, 0.9634, 0.7413, and 0.6526 for the PD models for
ALT, HMGB1, K18, and fragmented K18, respectively, it is
shown that the in silico model recapitulates in vivo experimen-
tal dynamics. Optimized parameters for all of the PK/PD mod-
els can be found in the Supplementary Table S1.
The R50 parameter in the biomarker PD models defines a
concentration of GSH at which the biomarker has reached
half of its maximal production rate (MPR). For biomarkers
ALT, HMGB1, K18, and fragmented K18, the R50 values were
227.67, 399.08, 212.87, and 72.09 lmol/L, respectively.
Therefore, in the model, as GSH is depleted from a baseline
of 696.91 lmol/L36 and reaches a concentration 399.08 lmol/
L (42.73% depletion), HMGB1 has reached half of its MPR
and is, therefore, considered to be the fastest responding bio-
marker. GSH must be further depleted to 227.67 lmol/L and
212.87 lmol/L (67–69% depletion), respectively, before bio-
markers ALT and K18 reach half of their MPR. Approximately
90% GSH depletion is required for fragmented K18 to reach
half of its MPR in the model.
Identifying time/dose category following APAP dose
Projecting the in silico derived data onto the principal compo-
nents and visualizing with respect to time-since-administration
and dose amount, as can be seen in Figure 2a,b, allowed
classes to be clearly distinguished with minimal level of over-
lap confirming the biomarker utility in class prediction. The
level of class overlap with respect to dose is significantly
lower. Visualizing the data with the T-SNE method (Figure 2c-
d) enhances the previous visualization, and that dose may be
separated more accurately. Additionally, the time-since-
administration classes are more separable with the T-SNE
method, particularly with earlier time ranges.
The classification results are consistent across the different
methodologies (Table 1). Should a new observation arise, this
framework could predict which “time-since-administration” and
“dose” category it should be placed in with 73.7% and 86.5%
accuracies, respectively. The results of the linear regression
model used to evaluate time-since-administration and initial
dose, both as continuous variables, are reported in Table 2. In
both cases, the model is significant at the 99% confidence
level. The R2 values indicate that when predicting time-since-
administration, 53% of the variance in results can be
explained by the model, whereas when predicting dose 80%
of the variation can be explained by the model. An exact time-
since-administration value was able to be predicted with a
residual standard error and accuracy of 3.6 hours, whereas an
exact dose was predicted with only an error of 56.81 mg/kg.
Figure 2 Visualization and classification of time-since-administration and dose results. For time-since-administration, dark green represents
class 0–2, orange represents 2–5, blue represents 5–10, pink represents 10–15, and pale green represents 15–24 hours. For dose, green
represents 0–200, orange represents 201–400, and blue represents 401–600 mg/kg. (a, b) Two-dimensional Principal Components Analysis
(PCA) visualization of in silico mouse observations with respect to time-since-administration and dose, respectively. (c, d) Two-dimensional
TSNE visualization of in silico mouse observations with respect to time-since-administration and dose, respectively.
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Predicting the probability of liver injury following an
APAP dose
From the forward-stepwise logistic regression analysis, the
model that used HMGB1 concentration alone as a predictor
had the highest significance (P value 0.003). Figure 3a-f
represents the fold-changes in biomarker concentrations
with respect to time following various doses. For higher
doses, APAP and related toxicity biomarker concentrations
are significantly increased during the time course, whereas
GSH is significantly decreased at higher doses, represent-
ing depletion of stores. Figure 3g shows how the probabil-
ity of serious liver injury (dependent only on HMGB1
concentration as predicted by the logistic regression model)
changes over time for doses between 0 and 600 mg/kg. A
threshold probability of 0.5 (i.e., 50% liver injury likelihood)
was used to determine likeliness of DILI. Any observation
within the white contour boundary is, therefore, predicted
likely to be a concentration representative of liver injury
(i.e., 50% chance). For lower toxic doses, according to the
model, HMGB1 concentrations that likely indicate liver
injury are most apparent between 5 and 10 hours postdose.
As the dose increases, the time frame increases to 5–15
hours. Note that combinations of APAP/ALT and APAP/full
K18 were also significant; therefore, these biomarker com-
binations could be investigated in the case of predicting
DILI following late presentation of paracetamol toxicity and
prognosis within the 24-hour window.
Currently, toxicity is thought to be apparent in mice after a
300 mg/kg dose, shown by the red line in Figure 3g. Our
binary logistic regression (model based solely on HMGB1
concentration) states there is >50% chance of liver injury at
a 200 mg/kg dose, shown by the white contour in Figure 3g.
The currently used toxic dose (300 mg/kg) coincides with
around 90% GSH depletion, which can be seen in Figure 3b.
This coincides with a relationship well known in the litera-
ture.13 This toxic level is also the dose at which fragmented
K18 begins to elevate, as shown in Figure 3f. The toxic
dose proposed by the in silico model (200 mg/kg) is the
dose at which ALT and full K18 begin to elevate (Figure 3c
and Figure 3e, respectively) and HMGB1 first reaches peak
concentration (Figure 3d).
Visualizing the probability of liver injury following an
APAP dose
Combining the PCA/T-SNE analysis with our proposed
framework for predicting the probability of liver injury
allowed the virtual datasets to be visualized not only with
regard to the initial dose and time since ingestion, but
also the subsequent probability of liver injury. With refer-
ence to Figure 4, observations with a high probability of
liver injury are clearly clustered within the parameter
space and separable from low probability cases. Addi-
tional similar projections (with both the PCA and T-SNE
methods), including the estimated maximum probability of
liver injury for each observation, are shown in the Supple-
mentary Material.
DISCUSSION
The current clinical framework for predicting whether or
not APAP antidote treatment is necessary is highly depen-
dent upon information provided by the patient, such as
when the dose was taken and in what quantity. This infor-
mation is often vague and/or unreliable. Consequently,
critically vulnerable patients are often left untreated or,
conversely, NAC is unnecessarily administered. Changes
in legislation have already led to an estimated increased
cost of £8.3 million per year due to overused NAC treat-
ment.37 Mathematical and statistical analysis provide a
proof-of-concept tool to predict information with a much
higher level of certainty, based on a panel of promising
biomarkers.
We have developed an optimized PK/PD model for APAP
and appropriate biomarkers of liver injury in a systems toxi-
cology approach. The model was used to conduct investi-
gations within a dosing range of 0–600 mg/kg without any
Table 1 Classification results for several algorithms with respect to time-
since-administration and dose, respectively, with numbers representing lev-
els of accuracy
Classification method Time accuracy Dose accuracy
Multinomial logistic regression 0.728 0.865
Ordinal multinomial logistic regression 0.570 0.859
Naive Bayes 0.689 0.844
Linear discriminant analysis 0.657 0.860
Quadratic discriminant analysis 0.737 0.853
K-nearest neighbor 0.664 0.859
Optimal weighted nearest neighbor 0.676 0.858
For example, the multinomial logistic regression model can predict time-
since-administration with 72.8% accuracy.
Table 2 Multiple linear regression analysis results - summary statistics for
models used to predict both time-since-administration and dose
Dependent variable
(coefficient and related error)
Time (1) Dose (2)
APAP concentration -18.141***
(1.095)
445.602***
(13.865)
ALT concentration 2.402**
(0.988)
94.724***
(12.830)
HMGB1 concentration -15.928***
(0.636)
Full K18 concentration 8.964***
(0.837)
241.527***
(12.958)
Fragmented K18 concentration 310.574***
(13.260)
Constant 14.812***
(0.268)
67.068***
(3.193)
Observations
Residual SE (df5994)
1,000
3.593
1,000
56.805
The first number in each element of the table represents the biomarker coef-
ficient in the regression model, whereas the second number represents the
coefficient’s corresponding error. For example, 218.141 is the APAP con-
centration coefficient in the model predicting time-since-administration, and
this coefficient has an error of 1.095. The significance of each biomarker in
the model is indicated by the number of asterisks *P< 0.1; **P< 0.05;
***P<0.01.
ALT, alanine aminotransferase; APAP, acetaminophen.
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further in vivo testing. The optimized in silico framework is
suitable for use in further theoretical investigations, provid-
ing a greater scope for reducing the dependency on animal
testing in toxicity and complying with the 3Rs principles.14
For example, results from our analysis could improve
experimental refinement, such as predicting the probability
of liver injury and toxicity at 200 mg/kg in mice rather than
300 mg/kg. Not only may experimentalists be dosing mice
at amounts higher than necessary, they may also be miss-
ing vital information apparent at lower doses.
APAP-induced liver toxicity is thought to occur when
GSH depletes by around 80–90%,13 which coincided with
elevated fragmented K18 levels. The in silico PD model
and its reported R50 values suggest that levels of HMGB1,
ALT, and full K18 elevate prior to this depletion level, elevat-
ing at 43%, 67%, and 69%, respectively. As a result,
HMGB1 in particular could be considered as an earlier indi-
cator of DILI.
The identification of more accurate predictions of dose
timing and amount, informed by biomarker concentration
samples, will improve nomogram treatment line accuracy.6
Predictions for the time-since-administration were success-
fully categorized into 0–2, 2–5, 5–10, 10–15, and 15–24-
hour ranges based on APAP, ALT, HMGB1, and full K18
concentration values with 73.7% accuracy. Should this
framework be translated to a similar level of efficiency in
the human clinical case, this information will have impact
regarding the determination of the potential liver injury,
Figure 3 (a–f) Fold-changes in biomarker concentration relative to their baseline values over time 0–24 hours for acetaminophen
(APAP), glutathione (GSH), alanine aminotransferase (ALT), HMGB1, full K18, and fragmented K18, respectively, following APAP doses
ranging from 0–600 mg/kg. (g) Proposed framework for predicting probability of liver injury dependent upon dose, time, and HMGB1
concentration. The white contour indicates the threshold of probability 0.5 of liver injury, the red dashed-line represents currently used
APAP dose for toxicity studies in mice, the white dashed-line represents toxic dose proposed by our model, and the green dashed-line
indicates current known therapeutic dose for mice.
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with less dependency on patient information. Additionally,
an exact value was predicted with an accuracy of 3.6
hours. Similarly, initial dose was able to be classified into
0–200, 201–400, and 401–600 mg/kg categories with
86.5% accuracy and an exact dose predicted with an
expected error of6 56.81 mg/kg. A panel of biomarker
measurements could be used in this manner to provide
the dose and time information, which will identify a (time-
dose) point on the liver injury framework, provided in Fig-
ure 3g, from which one can read off an instantaneous
probability of liver injury and how this probability is pre-
dicted to change as time progresses. Obtaining dose and
time information based on biomarker concentrations and
combining this with our proposed liver injury framework
shows the utility of these biomarkers in predicting dose
amount, time since ingestion, and the subsequent proba-
bility of liver injury.
Although ALT concentration is currently used as a clinical
measure to inform potential toxicity, it was found to have
the least importance in the regression model for predicting
time-since-administration as a continuous variable. Out of
all the biomarkers used in the multiple linear regression
analysis, HMGB1 was found to have the highest time-
since-administration model coefficient. This analysis sug-
gests, therefore, that not only is HMGB1 an earlier indicator
of DILI, but it is also an important biomarker in accurately
predicting the time elapsed since administration. Further-
more, logistic regression analysis identified HMGB1 as the
most significant predictor for liver injury, in line with recent
studies defining HMGB1 as a more sensitive DILI predic-
tor.38 As noted above, the focus of this work has been the
biomarkers that work well for DILI prediction due to APAP,
in which case HMGB1 is highlighted by our analysis. How-
ever, for different drugs, DILI may involve different mecha-
nisms and, as such, HMGB1 may not perform so well as a
singular biomarker but instead a panel would be more
predictive.
Although the results from the T-SNE method for visuali-
zation showed clear separation, particularly with regard to
the probability of liver injury, there was a slight overlap in
the time-since-administration and dose plots. This result
supports the possibility of defining further classes through
unsupervised methodologies in future investigations. The
classification techniques used provided incredibly high
accuracy levels considering the nature of the problem. A
further investigation of interest is the rate of misclassifica-
tion between the classes with regard to critical errors at the
edges of the variable ranges.
The framework proposed has the potential for substantial
clinical impact once translated to human. The analysis was
applied to mice due to the relative abundance and quality
of data (especially for toxicity cases) and the quantity of rel-
evant biomarker data required to properly characterize such
a mathematical and statistical predictive framework. Equiva-
lent APAP clinical data is available but has a tendency to
be noisy, sparse, and inconsistent. Analysis of such data
would, therefore, require the significant application of (top-
down) Pop-PK to unravel the stochasticity of the mixed-
effects involved, in addition to understanding and capturing
the mechanisms of the PK/PD problem. For example, the
relative influence of variation in certain model parameters
on quantitative model outputs can be determined by sensi-
tivity analysis, allowing for identification of mechanistic pro-
cesses that would require particularly careful consideration
when translating this model to a human clinical Pop-PK
framework (see Supplementary Materials for further
details).
An advantage of our study is that the same biomarkers
can be measured in both humans and animals by the
same methodologies. Moreover, the model hepatotoxin we
have used, acetaminophen, is directly comparable between
human and mice with respect to mechanism of toxicity and
action of the antidote. The major differences between
human and mouse studies are the mass dose of acetamin-
ophen needed to induce toxicity in mice and the kinetics of
the biomarker profile.25,39,40 The dose response in mice is
well documented and is consistent with our data. Further-
more, this can be adjusted as a parameter within our
model to reflect the clinical situation. There are a number
of clinical studies now published that have measured these
biomarkers from human studies in a time-dependent
way.41,42 The approach we describe to modify dose adjust-
ment can also be undertaken to reflect biomarker kinetic
differences. It is important to note that it is difficult to prop-
erly obtain or assess human pathology in the acute setting,
and it is only really in the event of liver transplantation that
we see a strong relationship between humans and
mice.25,43 Given the strong relationship between the bio-
marker signatures and mechanism of APAP action
between humans and mice, it would be reasonable to
translate findings from mouse acute data,25,39 to human
acute data.11 Taking these points into consideration, in its
current form, our framework is highly predictive and pro-
vides promise for clinical use in discriminating time-since-
administration, initial dose amount, and subsequent proba-
bility of liver injury. This would be a significant application
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mouse observations with respect to estimated probability of
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and could instruct the determination of NAC intervention in
patients suspected of APAP overdose.
Clinical assessment of DILI is, in practice, often based
on causality assessment, with expert opinion being the
gold standard, and does not wholly depend on simple
biochemical tests. We have recently discussed the poten-
tial improvement to laboratory-based measures in aiding
DILI assessment and one key feature we propose is that
laboratory measurements should be repeated when DILI
is suspected.11,44 This could allow for the determination
of the cause of injury as well as the derivation of the
area under the curve (AUC) of a liver toxicity marker. A
limitation of our current in silico model framework is that
it is focused on whether or not liver injury occurs, rather
than prediction of the maximum damage observed in an
individual. The cause of this limitation is the sparsity of the
histology data used for model parameterization. However,
if such additional AUC-based measurements could be
obtained, then this could potentially offer vital data to
extend the predictive potential of our in silico platform by
quantifying the maximal liver injury and further aiding DILI
assessment.
Source of Funding. C.L.M. acknowledges funding support from
the Faculty of Engineering and Technology, Liverpool John Moores Uni-
versity. J.L. acknowledges funding support from the Liverpool Centre for
Mathematics in Healthcare (EPSRC grant EP/N014499/1).
Conflict of Interest. The authors declared no competing interests
for this work.
Author Contributions. C.L.M., J.L., and S.D.W. wrote the manu-
script. D.J.A. and S.D.W. designed the research. C.L.M., J.L., and S.D.W.
performed the research. C.L.M., S.T., and I.J. analyzed the data. Daniel J.
Antoine and Steven D. Webb contributed to this work equally.
1. Chiew, A.L., Fountain, J.S., Graudins, A., Isbister, G.K., Reith, D. & Buckley, N.A.
Summary statement: new guidelines for the management of paracetamol poisoning in
Australia and New Zealand. Med. J. Aust. 203, 215–218 (2015).
2. Larson, A.M. et al. Acetaminophen-induced acute liver failure: results of a United
States multicenter, prospective study. Hepatology 42, 1364–1372 (2005).
3. Antoine, D.J. & Dear, J.W. How to treat paracetamol overdose and when to do it.
Expert Rev. Clin. Pharmacol. 9, 633–635 (2016).
4. Juurlink, D.N. Drug-induced hepatotoxicity. N. Engl. J. Med. 349, 1974–1976
(2003).
5. Rumack, B.H., Peterson, R.C., Koch, G.G. & Amara, I.A. Acetaminophen overdose.
662 cases with evaluation of oral acetylcysteine treatment. Arch. Intern. Med. 141(3
Spec No), 380–385 (1981).
6. GlaxoSmithKline. Guidelines for the management of paracetamol overdose [Internet].
<http://www.asem.org.au/document.php/njxudmy/Paracetamol1Overdose1Treatment1
Nomogram.pdf> (2007). Accessed 5 May, 2017.
7. Clarke, J.I., Dear, J.W. & Antoine, D.J. Recent advances in biomarkers and therapeu-
tic interventions for hepatic drug safety - false dawn or new horizon? Expert Opin.
Drug Saf. 15, 625–634 (2016).
8. BritishLiverTrust. Liver Function Tests [Internet]. <https://www.britishlivertrust.org.uk/
liver-information/tests-and-screening/liver-function-tests/> (2017). Accessed May 5,
2017.
9. Giannini, E.G., Testa, R. & Savarino, V. Liver enzyme alteration: a guide for clini-
cians. CMAJ 172, 367–379 (2005).
10. US Food and Drug Administration (FDA). Guidance for Industry Drug-Induced Liver
Injury: Premarketing Clinical Evaluation. Drug Safety [Internet]. July 28, 2009.
<https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/
ucm174090.pdf>.
11. Antoine, D.J. et al. Mechanistic biomarkers provide early and sensitive detection of
acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology
58, 777–787 (2013).
12. Beger, R.D. et al. Translational biomarkers of acetaminophen-induced acute liver
injury. Arch. Toxicol. 89, 1497–1522 (2015).
13. Hinson, J.A., Roberts, D.W. & James, L.P. Mechanisms of acetaminophen-induced
liver necrosis. Handb. Exp. Pharmacol. 196, 369–405 (2010).
14. National Centre for the 3Rs. The 3Rs (replacement, reduction, and refinement).
<https://www.nc3rs.org.uk/the-3rs> (2017). Accessed April 28, 2017.
15. Reith, D., Medlicott, N.J., Kumara De Silva, R., Yang, L., Hickling, J. & Zacharias, M.
Simultaneous modelling of the Michaelis-Menten kinetics of paracetamol sulphation
and glucuronidation. Clin. Exp. Pharmacol. Physiol. 36, 35–42 (2009).
16. Diaz Ochoa, J.G., Bucher, J., Pery, A.R., Zaldivar Comenges, J.M., Niklas, J. &
Mauch, K. A multi-scale modeling framework for individualized, spatiotemporal predic-
tion of drug effects and toxicological risk. Front. Pharmacol. 3, 204 (2013).
17. Remien, C.H., Adler, F.R., Waddoups, L., Box, T.D. & Sussman, N.L. Mathematical
modeling of liver injury and dysfunction after acetaminophen overdose: early discrimi-
nation between survival and death. Hepatology 56, 727–734 (2012).
18. Remien, C.H., Sussman, N.L. & Adler, F.R. Mathematical modelling of chronic acet-
aminophen metabolism and liver injury. Math. Med. Biol. 31, 302–317 (2014).
19. Ben-Shachar, R., Chen, Y., Luo, S., Hartman, C., Reed, M. & Nijhout, H.F. The bio-
chemistry of acetaminophen hepatotoxicity and rescue: a mathematical model. Theor.
Biol. Med. Model. 9, 55 (2012).
20. Reddyhoff, D., Ward, J., Williams, D., Regan, S. & Webb, S. Timescale analysis of a
mathematical model of acetaminophen metabolism and toxicity. J. Theor. Biol. 386,
132–146 (2015).
21. Shoda, L.K., Battista, C., Siler, S.Q., Pisetsky, D.S., Watkins, P.B. & Howell, B.A.
Mechanistic modelling of drug-induced liver injury: investigating the role of innate
immune responses. Gene Regul. Syst. Bio. 11, 1177625017696074 (2017).
22. Jaeschke, H., Xie, Y. & McGill, M.R. Acetaminophen-induced liver injury: from animal
models to humans. J. Clin. Transl. Hepatol. 2, 153–161 (2014).
23. Bateman, D.N. et al. Reduction of adverse effects from intravenous acetylcysteine
treatment for paracetamol poisoning: a randomised controlled trial. Lancet 383,
697–704 (2013).
24. Coen, M. et al. Integrated application of transcriptomics and metabonomics yields
new insight into the toxicity due to paracetamol in the mouse. J. Pharm. Biomed.
Anal. 35, 93–105 (2004).
25. Antoine, D.J. et al. High-mobility group box-1 protein and keratin-18, circulating serum
proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxi-
col. Sci. 112, 521–531 (2009).
26. Metzler, C.M. Usefulness of the two-compartment open model in pharmacokinetics. J.
Am. Stat. Assoc. 66, 49–53 (2012).
27. Wright, M.H. Nelder, Mead, and the Other Simplex Method. <http://www.math.uiu-
c.edu/documenta/vol-ismp/42_wright-margaret.pdf> (2010). Accessed May 12, 2017.
28. MathWorks. Matlab. <https://www.mathworks.com> (2016).
29. Sharma, A. & Jusko, W.J. Characteristics of indirect pharmacodynamic models and
applications to clinical drug responses. Br. J. Clin. Pharmacol. 45, 229–239 (1998).
30. Williams, D.P. et al. The metabolism and toxicity of furosemide in the Wistar rat and
CD-1 mouse: a chemical and biochemical definition of the toxicophore. J. Pharmacol.
Exp. Ther. 322, 1208–1220 (2007).
31. Ambrosius, W.T. Multiple linear regression. 165–187 In: Topics in Biostatistics.
(Humana Press, Totowa, New Jersey, 2007).
32. Jeong, D.H., Ziemkiewicz, C., Ribarsky, W. & Chang, R. Understanding principal
component analysis using a visual analytics tool. 1–10 <https://www.scribd.com/
document/130661529/Understanding-Principal-Component> (2009).
33. Van Der Maaten, L. Accelerating t-SNE using tree-based algorithms. J. Mach. Learn.
Res. 15, 3221–3245 (2014).
34. Bewick, V., Cheek, L. & Ball, J. Statistics review 14: logistic regression. Crit. Care 9,
112–118 (2005).
35. Brannick, M. Logistic regression. <http://faculty.cas.usf.edu/mbrannick/regression/
Logistic.html> (2016). Accessed April 28, 2017.
36. Antoine, D.J. Chemical and molecular markers of hepatic drug bioactivation,
apoptosis and necrosis. University of Liverpool. <http://ethos.bl.uk/Order-
Details.do?uin5uk.bl.ethos.501593> (2009).
37. Bateman, D.N. et al. Effect of the UK’s revised paracetamol poisoning management
guidelines on admissions, adverse reactions and costs of treatment. Br. J. Clin. Phar-
macol. 78, 610–618 (2014).
38. Lea, J.D., Clarke, J.I., McGuire, N. & Antoine, D.J. Redox-dependent HMGB1 iso-
forms as pivotal co-ordinators of drug-induced liver injury: mechanistic biomarkers
and therapeutic targets. Antioxid. Redox Signal. 24, 652–665 (2016).
39. Brillant, N. et al. Dynamic and accurate assessment of acetaminophen-induced hepa-
totoxicity by integrated photoacoustic imaging and mechanistic biomarkers in vivo.
Toxicol. Appl. Pharmacol. 332, 64–74 (2017).
40. Antoine, D.J. et al. Molecular forms of HMGB1 and keratin-18 as mechanistic bio-
markers for mode of cell death and prognosis during clinical acetaminophen hepato-
toxicity. J. Hepatol. 56, 1070–1079 (2012).
41. Dear, J.W. et al. Risk stratification after paracetamol overdose using mechanistic bio-
markers: results from two prospective cohort studies. Lancet Gastroenterol. Hepatol.
3, 104–113 (2018).
Predicting Paracetamol Toxicity
Mason et al.
9
www.psp-journal.com
42. Longo, D.M. et al. Refining liver safety risk assessment: application of mechanistic
modeling and serum biomarkers to cimaglermin alfa (GGF2) clinical trials. Clin. Phar-
macol. Ther. 102, 961–969 (2017).
43. Bechmann, L.P., Marquitan, G., Jochum, C., Saner, F., Gerken, G. & Canbay, A. Apopto-
sis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxi-
cation compared with acute-on-chronic liver failure. Liver Int. 28, 713–716 (2008).
44. Antoine, D.J. Laboratory-based biomarkers to improve causality assessment in drug-
induced liver injury. Clin. Liver Dis. (Hoboken) 9, 38–42 (2017).
VC 2018 The Authors CPT: Pharmacometrics & Systems
Pharmacology published by Wiley Periodicals, Inc. on
behalf of American Society for Clinical Pharmacology and
Therapeutics. This is an open access article under the
terms of the Creative Commons Attribution License, which
permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website
(http://psp-journal.com)
Predicting Paracetamol Toxicity
Mason et al.
10
CPT: Pharmacometrics & Systems Pharmacology
